Ocuphire Pharma Investor Updates

P 19 Percent of Subjects (%) Change in Photopic and Mesopic BCDVA at the 1-Hour Timepoint Treatment With Nyxol And/Or LDP Did Not Reduce BCDVA And Had A Modest Beneficial Effect 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects With Improvement or Loss From Baseline in Photopic BCDVA at 1 Hour 91% *p<0.05 9% 28% 20% 19% 72% 77% 74% >= 5 Letters Placebo (n=44) Nyxol+LDP (n=43) Nyxol (n=30) Within 5 Letters VEGA-1 Phase 2 Trial 0% 0% 3% <= -5 Letters LDP (n=31) 7% Percent of Subjects (%) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Percent of Subjects With Improvement or Loss From Baseline in Mesopic BCDVA at 1 Hour 84% 9% 23% 27% 39% >= 5 Letters Placebo (n=43) 72% 73% 55% Within 5 Letters Nyxol+LDP (n=43) Nyxol (n=30) Source: VEGA-1 TLR Table 14.2.8.1 and 14.2.10.1 Percent of Subjects With Improvement or Loss From Baseline in Photopic and Mesopic BCDVA by Time Point (PP) 7% 5% 0% <= -5 Letters LDP (n=31) 7% Ocuphire PHARMA

View entire presentation